

# Critical immunotherapy target marks dysfunctional regulatory T cells in brain cancer

April 21 2016

---

Immunotherapy represents an exciting advance in cancer treatment that harnesses the immune system to seek and destroy cancer cells. The programmed death 1 (PD-1) pathway dampens immune responses to tumor cells, and several clinical trials have shown favorable outcomes by targeting PD-1 or its ligand PD-1L.

In this issue of *JCI Insight*, David Hafler and colleagues at Yale University and Massachusetts Institute of Technology examined PD-1-expressing regulatory T cells in glioblastoma multiforme, an extremely aggressive form of brain cancer. Regulatory T cells normally constrain immune responses and keep other types of T cells from mounting hyper-aggressive responses.

Although anti-PD1 therapy is generally thought to promote conventional T cell activity, the Hafler team now reports that PD-1 expression on regulatory T cells from the tumors of glioblastoma multiforme patients correlates with regulatory T cell dysfunction.

They also found that glioblastoma multiforme patients treated with a PD-1 blocking antibody had a higher proportion of dysfunctional regulatory T cells. These observations suggest the possibility that PD-1 targeting therapies could work, in part, by driving further regulatory T [cell dysfunction](#).

Future studies will be needed to more fully understand the contribution of this pathway to anti-tumor effects.

**More information:** Daniel E. Lowther et al, PD-1 marks dysfunctional regulatory T cells in malignant gliomas, *JCI Insight* (2016). DOI: [10.1172/jci.insight.85935](https://doi.org/10.1172/jci.insight.85935)

Provided by Journal of Clinical Investigation

Citation: Critical immunotherapy target marks dysfunctional regulatory T cells in brain cancer (2016, April 21) retrieved 20 December 2022 from <https://medicalxpress.com/news/2016-04-critical-immunotherapy-dysfunctional-regulatory-cells.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.